Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Documenti analoghi

• Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study
  di: Midori Shima, et al.
  Pubblicazione: (2026)
• TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
  di: Kagehiro Amano, et al.
  Pubblicazione: (2025)
• The First Three Japanese Haemophilia A Patients in Whom Factor VIII Inhibitors Were Observed During Prophylactic Treatment With Efanesoctocog Alfa
  di: Tazuko Tokugawa, et al.
  Pubblicazione: (2025)
• Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
  di: Branislav V. Bajkin, et al.
  Pubblicazione: (2026)
• Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis
  di: Han Bao, et al.
  Pubblicazione: (2026)